# A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

> **NCT05283720** · PHASE2 · RECRUITING · sponsor: **Genmab** · enrollment: 496 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Lenalidomide
- **DRUG:** Ibrutinib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride [HCl]
- **DRUG:** Prednisone
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** CC-99282

## Key facts

- **NCT ID:** NCT05283720
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-14
- **Primary completion:** 2032-11
- **Final completion:** 2032-11
- **Target enrollment:** 496 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- AbbVie

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283720, "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05283720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*